A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

NCT01283516 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors Characterized by Genetic Abnormalities of ALK

Interventions

DRUG: LDK378

Sponsor

Novartis Pharmaceuticals